PaxMedica, SurgePays, Opal Fuels And More Short Squeeze Candidates That Could Soar This Week
Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move.
Getty Images, MoonLake And 3 Other Short Squeeze Candidates That May Soar This Week
Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move.
Surgepays Q3 EPS $(0.12) Misses $0.29 Estimate, Sales $36.17M Beat $33.33M Estimate
Surgepays (NASDAQ:SURG) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $0.29 by 141.38 percent. The company reported quarterly sales of $36.17 million which beat the
Earnings Scheduled For November 14, 2022
Companies Reporting Before The Bell
• Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.
Getty Images, MicroStrategy And 3 More Short Squeeze Stocks That Could Soar This Week
Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move.
TOP Ships, Weber And 3 More Short Squeeze Stocks That Could Soar This Week
Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move.
Here’s a look at the top five short squeeze candidates based on the Fintel short squeeze leaderboard.
Grenwich LilfeSciences, Blue Apron And 3 More Short Squeeze Candidates That May Soar
Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move.
Here’s a look at the top five short squeeze candidates for the week of Oct. 3 based on the Fintel short squeeze leaderboard.
5 Short Squeeze Stocks That Could Soar: NeruoBo Pharmaceuticals, FaZe Holdings And More
Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move.
Here’s a look at the top five short squeeze candidates for the week of Sept. 19, according to Fintel Data:
Looking Into Surgepays’s Return On Capital Employed
According to Benzinga Pro data, during Q2, Surgepays (NASDAQ:SURG) posted sales of $28.00 million. Earnings were up 28.36%, but Surgepays still reported an overall loss of $891 thousand.
Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday
Gainers
Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results.